source
- Real-World Data Highlight Survival Benefit of Rituximab Maintenance After Frontline BR in MCLRituximab following first-line bendamustine demonstrated significant OS and EFS real-world benefits in mantle cell lymphoma.onclive · 2mo ago↗ source
- Dr Silbermann on Clinical Trial Design Considerations in Multiple MyelomaRebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.onclive · 2mo ago↗ source
- Retrospective Data Show Potential Real-World TTNT and OS Improvements With Next-Generation BTK Inhibitors in R/R MCLRetrospective data showed zanubrutinib was associated with improved real-world overall survival vs ibrutinib in second- or third-line mantle cell lymphoma.